The estimated Net Worth of Hong Yu is at least 1.65 百万$ dollars as of 7 December 2022. Mr Yu owns over 83,676 units of Biostage stock worth over 896,510$ and over the last 6 years he sold BSTG stock worth over 599,957$. In addition, he makes 157,950$ as Pres at Biostage.
Mr has made over 3 trades of the Biostage stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 83,676 units of BSTG stock worth 599,957$ on 7 December 2022.
The largest trade he's ever made was selling 83,676 units of Biostage stock on 7 December 2022 worth over 599,957$. On average, Mr trades about 20,946 units every 273 days since 2018. As of 7 December 2022 he still owns at least 222,459 units of Biostage stock.
You can see the complete history of Mr Yu stock trades at the bottom of the page.
Yu Hong is the Pres at Biostage.
As the Pres of Biostage, the total compensation of Mr Hong at Biostage is 157,950$. There are 2 executives at Biostage getting paid more, with David Green having the highest compensation of 534,506$.
Mr Hong is 48, he's been the Pres of Biostage since . There are 5 older and 1 younger executives at Biostage. The oldest executive at Biostage, Inc. is James Shmerling, 63, who is the Director.
Hong's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 8 years, insiders at Biostage have traded over 962,849$ worth of Biostage stock and bought 1,593,581 units worth 3,804,230$ . The most active insiders traders include David Green、Capital Llc Dst、Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of 217,604$. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth 375,000$.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage executives and other stock owners filed with the SEC include: